On June 2, 2025, Vera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept, aimed at treating immunoglobulin A nephropathy (IgAN) in adults, successfully met its primary endpoint. Participants receiving atacicept achieved a 46% reduction in proteinuria from baseline and a 42% reduction compared to placebo. Vera plans to submit a Biologics License Application $(BLA.AU)$ for accelerated approval to the FDA in the fourth quarter of 2025, potentially paving the way for a U.S. approval and commercial launch in 2026. The company is preparing for a potential commercial launch and further development in additional indications for autoimmune kidney diseases. Vera will host an investor call and webcast to discuss these findings and the regulatory pathway.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.